AI Article Synopsis
- Progress in treating multiple myeloma over the past ten years has improved outcomes, but many patients still face resistance and related complications, leading to death.
- New drug developments, including alkylating agents, proteasome inhibitors, immunomodulators, monoclonal antibodies, and innovative medications, aim to tackle this issue.
- The goal of these targeted therapies is to enhance initial treatment effectiveness, reduce relapses and resistance, and offer safer options for patients who have relapsed or are resistant to existing treatments.
Article Abstract
Progress in the treatment of multiple myeloma in the last decade has been able to delay, but ultimately not to prevent, the development of resistances and most patients still die of the disease or its related complications. New drugs have been developed including new alkylating agents, proteasome inhibitors and immunomodulators but also monoclonal antibodies and drugs with new mechanisms of action. Hopefully, this new generation of targeted agents will improve the results of the initial therapy, avoid relapses and development of resistances and provide better and less toxic options for the relapsed and refractory patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2013.10.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!